Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.

Aliasghar Ahmad Kiadaliri; Ulf Gerdtham; Bjorn Eliasson; Katarina Steen Carlsson

doi:10.1007/s13300-014-0080-0

Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.

Aliasghar Ahmad Kiadaliri, Ulf Gerdtham, Bjorn Eliasson, Katarina Steen Carlsson

Research output: Contribution to journal › Article › peer-review

246 Downloads (Pure)

Abstract

This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin.

Original language	English
Pages (from-to)	591-607
Journal	Diabetes therapy : research, treatment and education of diabetes and related disorders
Volume	5
Issue number	2
DOIs	https://doi.org/10.1007/s13300-014-0080-0
Publication status	Published - 2014

Subject classification (UKÄ)

Endocrinology and Diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s13300-014-0080-0

Springer__Ahmad_Kiadaliri_et_al

http://www.ncbi.nlm.nih.gov/pubmed/25213800?dopt=Abstract

1 Doctoral Thesis (compilation)

Towards a Health Economic Simulation Model of Type 2 Diabetes in Sweden
Ahmad Kiadaliri, A., 2014, Health Economics. 57 p.
Research output: Thesis › Doctoral Thesis (compilation)

File

Cite this

Ahmad Kiadaliri, A., Gerdtham, U., Eliasson, B., & Steen Carlsson, K. (2014). Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. Diabetes therapy : research, treatment and education of diabetes and related disorders, 5(2), 591-607. https://doi.org/10.1007/s13300-014-0080-0

Ahmad Kiadaliri, Aliasghar ; Gerdtham, Ulf ; Eliasson, Bjorn et al. / Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. In: Diabetes therapy : research, treatment and education of diabetes and related disorders. 2014 ; Vol. 5, No. 2. pp. 591-607.

@article{bfa68c70de5f4f5fa7657e7d34ec5ab2,

title = "Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.",

abstract = "This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin.",

author = "{Ahmad Kiadaliri}, Aliasghar and Ulf Gerdtham and Bjorn Eliasson and {Steen Carlsson}, Katarina",

year = "2014",

doi = "10.1007/s13300-014-0080-0",

language = "English",

volume = "5",

pages = "591--607",

journal = "Diabetes therapy : research, treatment and education of diabetes and related disorders",

issn = "1869-6953",

publisher = "Springer",

number = "2",

}

Ahmad Kiadaliri, A , Gerdtham, U, Eliasson, B & Steen Carlsson, K 2014, 'Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.', Diabetes therapy : research, treatment and education of diabetes and related disorders, vol. 5, no. 2, pp. 591-607. https://doi.org/10.1007/s13300-014-0080-0

Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. / Ahmad Kiadaliri, Aliasghar ; Gerdtham, Ulf; Eliasson, Bjorn et al.
In: Diabetes therapy : research, treatment and education of diabetes and related disorders, Vol. 5, No. 2, 2014, p. 591-607.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.

AU - Ahmad Kiadaliri, Aliasghar

AU - Gerdtham, Ulf

AU - Eliasson, Bjorn

AU - Steen Carlsson, Katarina

PY - 2014

Y1 - 2014

N2 - This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin.

AB - This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin.

U2 - 10.1007/s13300-014-0080-0

DO - 10.1007/s13300-014-0080-0

M3 - Article

C2 - 25213800

SN - 1869-6953

VL - 5

SP - 591

EP - 607

JO - Diabetes therapy : research, treatment and education of diabetes and related disorders

JF - Diabetes therapy : research, treatment and education of diabetes and related disorders

IS - 2

ER -

Ahmad Kiadaliri A , Gerdtham U, Eliasson B, Steen Carlsson K. Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2014;5(2):591-607. doi: 10.1007/s13300-014-0080-0

Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Research output

Towards a Health Economic Simulation Model of Type 2 Diabetes in Sweden

Cite this